Natixis Advisors’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$43M Buy
708,704
+66,776
+10% +$3.89M 0.06% 302
2025
Q4
$34.6M Buy
641,928
+51,668
+9% +$2.49M 0.05% 336
2025
Q3
$26.6M Buy
590,260
+44,698
+8% +$2.09M 0.04% 398
2025
Q2
$25.3M Sell
545,562
-246,105
-31% -$12.1M 0.04% 394
2025
Q1
$48.3M Buy
791,667
+110,826
+16% +$6.46M 0.09% 237
2024
Q4
$38.5M Buy
680,841
+234,477
+53% +$13.1M 0.07% 272
2024
Q3
$23.1M Buy
446,364
+115,361
+35% +$5.41M 0.05% 377
2024
Q2
$13.7M Sell
331,003
-288,365
-47% -$12.9M 0.03% 501
2024
Q1
$33.6M Buy
619,368
+31,147
+5% +$1.59M 0.08% 266
2023
Q4
$30.2M Sell
588,221
-251,441
-30% -$13.2M 0.08% 263
2023
Q3
$48.7M Sell
839,662
-135,150
-14% -$8.28M 0.15% 156
2023
Q2
$62.3M Buy
974,812
+47,253
+5% +$3.17M 0.19% 128
2023
Q1
$64.3M Sell
927,559
-44,195
-5% -$3.12M 0.22% 119
2022
Q4
$69.9M Sell
971,754
-22,411
-2% -$1.69M 0.26% 102
2022
Q3
$70.7M Sell
994,165
-94,666
-9% -$6.87M 0.3% 82
2022
Q2
$83.8M Buy
1,088,831
+159,481
+17% +$12.1M 0.37% 65
2022
Q1
$67.9M Buy
929,350
+167,418
+22% +$11.2M 0.26% 94
2021
Q4
$47.5M Buy
761,932
+67,957
+10% +$3.99M 0.18% 134
2021
Q3
$41.1M Sell
693,975
-145,531
-17% -$9.58M 0.17% 143
2021
Q2
$56.1M Buy
839,506
+68,453
+9% +$4.46M 0.26% 88
2021
Q1
$48.7M Buy
771,053
+42,102
+6% +$2.62M 0.25% 91
2020
Q4
$45.2M Buy
728,951
+46,444
+7% +$2.86M 0.26% 81
2020
Q3
$41.1M Sell
682,507
-30,603
-4% -$1.84M 0.26% 83
2020
Q2
$41.9M Buy
713,110
+80,441
+13% +$4.81M 0.28% 75
2020
Q1
$35.3M Buy
632,669
+1,836
+0.3% +$112K 0.29% 76
2019
Q4
$40.5M Buy
630,833
+116,396
+23% +$6.67M 0.29% 73
2019
Q3
$26.1M Buy
514,437
+237,630
+86% +$11.2M 0.21% 114
2019
Q2
$12.6M Buy
276,807
+109,365
+65% +$5.09M 0.1% 222
2019
Q1
$7.99M Sell
167,442
-11,226
-6% -$559K 0.07% 312
2018
Q4
$9.29M Buy
178,668
+2,997
+2% +$161K 0.09% 242
2018
Q3
$10.9M Buy
175,671
+9,214
+6% +$547K 0.1% 236
2018
Q2
$9.21M Sell
166,457
-21,073
-11% -$1.14M 0.09% 269
2018
Q1
$11.9M Buy
187,530
+17,849
+11% +$1.15M 0.12% 197
2017
Q4
$10.4M Buy
169,681
+1,322
+0.8% +$82.7K 0.11% 227
2017
Q3
$10.7M Buy
168,359
+47,888
+40% +$2.8M 0.11% 209
2017
Q2
$6.71M Sell
120,471
-67,705
-36% -$3.68M 0.07% 328
2017
Q1
$10.2M Sell
188,176
-123,655
-40% -$6.78M 0.11% 219
2016
Q4
$18.2M Buy
311,831
+46,215
+17% +$2.53M 0.22% 104
2016
Q3
$14.3M Buy
265,616
+62,454
+31% +$4.01M 0.19% 135
2016
Q2
$14.9M Buy
203,162
+76,844
+61% +$5.43M 0.21% 114
2016
Q1
$8.07M Sell
126,318
-12,785
-9% -$806K 0.12% 203
2015
Q4
$9.57M Sell
139,103
-3,987
-3% -$263K 0.16% 160
2015
Q3
$8.47M Sell
143,090
-66,309
-32% -$4.21M 0.15% 171
2015
Q2
$13.9M Buy
209,399
+1,726
+0.8% +$114K 0.24% 89
2015
Q1
$13.4M Buy
207,673
+5,539
+3% +$347K 0.24% 90
2014
Q4
$11.9M Sell
202,134
-7,065
-3% -$398K 0.22% 92
2014
Q3
$10.7M Sell
209,199
-19,234
-8% -$961K 0.21% 101
2014
Q2
$11.1M Buy
228,433
+1,649
+0.7% +$81.3K 0.16% 185
2014
Q1
$11.8M Buy
226,784
+4,921
+2% +$262K 0.18% 167
2013
Q4
$11.8M Buy
221,863
+40,686
+22% +$2.07M 0.19% 147
2013
Q3
$8.38M Buy
181,177
+7,963
+5% +$350K 0.15% 218
2013
Q2
$7.74M Buy
+173,214
New +$7.52M 0.15% 224

Other funds holding BMY

Natixis Advisors's BMY Position: Q1 2026 in Review

Natixis Advisors increased its Bristol-Myers Squibb (BMY) stake by 10% in Q1 2026, buying an estimated $3.89M and bringing the position to 708,704 shares worth $43M. The position accounts for 0.06% of the portfolio, ranked #302.

Natixis Advisors first reported a position in BMY in Q2 2013 and has held it in 52 quarters since. The position peaked at $83.8M in Q2 2022. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Natixis Advisors held 708,704 shares of Bristol-Myers Squibb worth $43M as of Q1 2026.
  • Natixis Advisors bought 66,776 Bristol-Myers Squibb shares in Q1 2026, an estimated $3.89M.
  • Bristol-Myers Squibb made up 0.06% of Natixis Advisors's portfolio in Q1 2026, its #302 holding.
  • Natixis Advisors first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 52 quarters since.
  • Natixis Advisors's Bristol-Myers Squibb position peaked at $83.8M in Q2 2022.
  • 2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Natixis Advisors's 13F filing for Q1 2026, filed 13 May 2026.